Ordering
Available Variants10 mg
CHA.50556-10mg
Price
€79.12
Available – Dispatch in 14 days
50 mg
CHA.50556-50mg
Price
€319.20
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.50556-10mg | €79.12 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.50556-50mg | €319.20 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C19H21FN2O4 |
|---|---|
| CAS Number | 154357-42-3 |
| Molecular Weight | 360.38 |
| UNSPSC Code | 51111800 |
| NACRES | NA.21 |
| MDL number | MFCD09954130 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
Levonadifloxacin, with a CAS number of 154357-42-3, is a synthetic antibacterial agent belonging to the fluoroquinolone class of antibiotics. It exhibits broad-spectrum activity against a wide range of Gram-positive and Gram-negative bacteria, including strains resistant to other antibiotics. The mechanism of action of levonadifloxacin involves inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes for DNA replication and transcription. This results in the disruption of bacterial DNA synthesis, ultimately leading to the death of the bacterial cells. Levonadifloxacin has been investigated for its potential in treating various infections, including respiratory tract infections, skin and soft tissue infections, and urinary tract infections, due to its potent antibacterial activity and favorable pharmacokinetic profile, which allows for once-daily dosing and high tissue penetration. Its efficacy and safety have been evaluated in several clinical trials.
